Patient Safety Global Ministerial Summit Recognizes PSMF Founder Joe Kiani
6.9.2024 21:41:00 EEST | Business Wire | Press release
Global leaders in patient safety gathered for day one of the 11th Annual World Patient Safety, Science & Technology Summit to spotlight the most critical issues affecting patient safety. Held on the UC Irvine campus for the first time, the Patient Safety Movement Foundation’s (PSMF) annual meeting aims to build on progress made over the past decade toward eliminating preventable harm caused by medical error.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240906604830/en/
Patient Safety Movement Foundation Founder Joe Kiani is recognized by the Patient Safety Global Ministerial Summit at PSMF's annual World Patient Safety, Science & Technology Summit, which opened today. Dr. Mike Durkin, PSMF's board chair, presented the honor. (Photo: Business Wire)
After PSMF founder Joe Kiani provided the Summit’s opening remarks, the Patient Safety Global Ministerial Summit recognized him for his work in patient safety. “We recognize Joe Kiani with the deepest respect from the global community of families, experts, policymakers, and politicians in patient safety who have greatly benefited from his unwavering commitment to reducing avoidable harm to zero. His partnership with the World Health Organization, his contribution to the Global Patient Safety Action Plan, his outstanding leadership over many years at the Global Ministerial Summits on Patient Safety, and his drive and determination to ensure the ongoing advancement of science and technology across the global medical devices industries have ensured that our patients at every level and in every setting continue to benefit from his latest advances to reduce avoidable harm. The healthcare world is a safer environment because of his dedication, and both patients and healthcare workers will continue to reap the benefits of his excellence for decades to come.”
“I’m honored,” stated Joe Kiani. “The Patient Safety Global Ministerial Summit, the World Health Organization, and Dr. Tedros Adhanom Ghebreyesus have played a leading role in making patient safety a priority around the world. I believe that if we all work together, we have the tools and know-how to create a safer healthcare system for all. To get to zero, we have to implement evidence-based practices, and we need our board members and hospital C-suites demanding their implementation. There is great momentum, and we cannot stop until we reach ZERO preventable harm in our hospitals.”
Since their inception in 2016, the Global Ministerial Summits on Patient Safety have succeeded in raising awareness, as well as creating and sustaining the momentum of the global patient safety movement, as evidenced by the adoption of the WHA resolution (WHA72.6) “Global Action on Patient Safety” in May 2019, which enabled the first-ever World Patient Safety Day in September 2019.
Some of the world’s most prominent leaders in patient safety are presenting at the PSMF’s Summit this year, including Dr. Don Berwick, Senior Fellow at the Institute for Healthcare Improvements. In his keynote, Berwick will discuss how to ensure progress on improvements in patient safety remain at the forefront of the national conversation following last year’s recommendations to the US president in the PCAST report, “A Transformational Effort on Patient Safety.”
During the afternoon session, Dr. Craig Umscheid, Director of the Center for Quality Improvement and Patient Safety, Agency for Healthcare Research and Quality (AHRQ), will speak on AHRQ’s National Action Alliance for Patient and Workforce Safety, which takes a systems approach informed by safety self-assessments to improve patient and workforce safety across all healthcare delivery settings, with a goal of reducing harms by 50% from the pandemic peak in two years.
In her keynote, Dr. Michelle Schreiber, Director of Quality Measurement & Value Based Incentives Group, Center for Medicare and Medicaid Services (CMS), will detail the eight goals of CMS’s National Quality Strategy and outline CMS’s efforts to improve healthcare for all by promoting transparency and a safety culture through partnerships, while incentivizing zero harm.
The Summit’s first day will also include presentations from Dr. Diana Ramos, the Surgeon General of California; Dr. Peter Ziese, Head of Medical Innovation & Strategy at PHILIPS; Scott Hamilton Kennedy, an Academy Award-nominated documentary filmmaker; Dr. Evan Benjamin, Associate Professor of Medicine at Harvard Medical School; and Henrietta Hughes, the Patient Safety Commissioner for England.
Panel discussions will focus on advancements in using real-time data from electronic medical records, improving safety through systemwide collaboration, and the essential role hospital boards and the C-suite can play in fostering a culture of safety.
PATIENT SAFETY MOVEMENT FOUNDATION
In 2012, Joe Kiani founded the nonprofit Patient Safety Movement Foundation to eliminate preventable medical errors in hospitals. His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices that address top challenges. Hospitals can make a formal commitment to ZERO preventable deaths, and healthcare technology companies are asked to sign the Open Data Pledge to share their data so that predictive algorithms can be developed to identify errors before they become fatal. The PSMF was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240906604830/en/
Contacts
Patient Safety Movement Foundation
Irene Mulonni, irene@mulonni.com | (858) 859-7001
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom